851 studies found for:    "Hypercholesterolemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Hypercholesterolemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
2 Completed
Has Results
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: Mipomersen Sodium
3 Completed Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity.
Conditions: Familial Hypercholesterolemias;   Weight Loss;   Familial Combined Hypercholesterolemia;   Obesity
Intervention: Behavioral: Weight loss and dietary intervention
4 Completed
Has Results
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: Placebo
5 Completed Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
Condition: Hypercholesterolemia
Intervention:
6 Not yet recruiting A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
Conditions: Hypercholesterolemia;   Familial Hypercholesterolemia
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin
7 Active, not recruiting A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Conditions: Hypercholesterolemia;   Heterozygous Familial Hypercholesterolemia
Interventions: Drug: EZ 10 mg/Atorva 20 mg FDC;   Drug: EZ 10 mg/Atorva 10 mg FDC
8 Completed Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
9 Terminated
Has Results
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
Conditions: Hypercholesterolemia, Familial;   Heterozygous Familial Hypercholesterolemia
Intervention: Drug: MK-0524A
10 Completed
Has Results
Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Drug: Pitavastatin
11 Completed Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention: Drug: MD-0727
12 Withdrawn Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Interventions: Biological: Placebo;   Biological: 1 mg/kg every 2 weeks;   Biological: 2 mg/kg every 4 weeks;   Biological: 4 mg/kg every 4 weeks;   Biological: 4 mg/kg every 8 weeks;   Biological: 8 mg/kg every 8 weeks;   Biological: 12 mg/kg every 8 weeks
13 Not yet recruiting A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia
Conditions: Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions: Biological: Evolocumab;   Other: Placebo to Evolocumab
14 Completed Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Biological: PF-04950615 (RN316)
15 Completed Pan-European Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
16 Recruiting Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Conditions: Familial Hypercholesterolemia;   Lipid Disorder
Intervention:
17 Recruiting Study of Awareness and Detection of Familial Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
18 Not yet recruiting Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).
Condition: Familial Hypercholesterolemia
Intervention: Biological: evolocumab (AMG 145)
19 Completed Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
20 Completed Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Cardiovascular Disease;   Hypertension;   Diabetes;   Coronary Heart Disease;   Peripheral Arterial Disease
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years